This talk will summarise the burden of vaccine-preventable diseases - including influenza, COVID-19, respiratory syncytial virus, pneumococcus and herpes zoster - in people with asthma around the world illustrating the considerable burden in low-income and middle-income countries (LMICs). Current recommendations from WHO and others for vaccinating people with asthma against these diseases will be discussed and put in the context of the current global coverage of these through vaccination programmes. Growing evidence regarding the impact of herpes zoster in people with asthma will be highlighted and opportunities to reduce this burden through vaccination explored. The Gavi Vaccine Alliance has improved access to vaccines for millions of people in LMICs playing a critical role in strengthening primary health care, and helping to achieve the Sustainable Development Goal of Universal Health Coverage - what can be learned from the success of Gavi to improve access to affordable inhaled medicines for people with asthma in LMICs?
GAN gratefully acknowledges funding from the University of Auckland and Wellcome (Grant number 203919/Z/16/Z) as well as sponsorship from AstraZeneca and GlaxoSmithKline that has helped to make the GAN Symposium 2024 possible. We thank the speakers and the organisations they represent for their contributions including securing their own funding to enable their participation. The Symposium programme was developed independently by the GAN Steering Group.
Our network has been targeted by an email scam. If you receive any unusual requests for assistance from any of the steering group members, please ignore it.
These emails are a common scam that has also targeted many other organisations. Please note we will never make any request for financial assistance from our collaborators. If you have any questions please contact us at firstname.lastname@example.org